Authors: Goren A, Wambler CG, Herrera S, McCoy J, Gioia F
PMID: 32977363 PMCID: PMC7536996 DOI: 10.1111/jdv.16953
Abstract
The COVID-19 pandemic has disproportionally affected men.1 Men infected with SARS-CoV-2 are more than twice as likely to be admitted to the intensive care unit (ICU).2 This disparity in ICU admissions suggests the important role of androgens in COVID-19 severity.3 Previously, we reported that among 122 men hospitalized due to COVID-19, 79% were diagnosed with androgenetic alopecia (AGA),4 which is commonly treated with anti-androgens. Anti-androgens commonly used in the treatment of AGA such as finasteride, dutasteride, spironolactone, and bicalutamide could improve outcomes among men infected by SARS-CoV-2.
Keywords: Anti-androgens, COVID-19, SARS-CoV2
